WO_3-TiO_2/SBA-15的制备及其光催化氧化脱硫性能

采用孔道内水解法制备了WO_3-TiO_2/SBA-15催化剂用于光催化氧化柴油脱硫,利用XRD、SEM、EDS、N2吸附-脱附、FT-IR、TG-DTA和UV-vis等技术对该催化剂进行了表征,考察了WO_3和TiO_2负载量、焙烧温度和焙烧时间对其光催化氧化脱硫性能的影响。结果表明,WO3和Ti O2负载量分别为1.6%和15%,焙烧温度500℃,焙烧时间为3 h条件所制备的催化剂性能最佳;在该条件下制备的WO_3-TiO_2/SBA-15催化剂仍保持SBA-15的六方介孔结构,模拟柴油的脱硫率高达87.9%,且具有良好的回收再生性能。     

高效甲醇水蒸气重整制氢的SBA-15改性的Cu/ZnO/Al2O3催化剂

以介孔SBA-15为结构助剂, 制备出用于甲醇水蒸气重整制氢的新型高效氧化硅掺杂的Cu/ZnO/Al₂O₃催化剂, 并与传统Cu/ZnO/Al₂O₃催化剂在相同条件下的催化性能进行了比较. 结果表明, 添加适量介孔SBA-15可显著提高催化剂的催化活性和选择性, 在大幅度提高甲醇转化率的同时有效降低了重整产气中CO的含量. 原位XRD分析证实适量介孔SBA-15的添加对传统Cu/ZnO/Al₂O₃催化剂的微结构性质可产生重要的调控作用, 从而大大改善其催化活性和制氢选择性.     

Enhanced electrocatalytic degradation of 2,4-Dinitrophenol (2,4-DNP) in three-dimensional sono-electrochemical (3D/SEC) process equipped with Fe/SBA-15 nanocomposite particle electrodes: Degradation pathway and application for real wastewater

2,4-dinitrophenol (2,4-DNP), which is a nitrophenol compound, is a carcinogenic and non-biodegradable pollutant, which is found at high concentrations in industrial wastewater. Degradation of 2,4-DNP using a three-dimensional sono-electrochemical (3D/SEC) process equipped with G/β-PbO₂ anode and Fe/SBA-15 nanocomposite particle electrodes was evaluated in the present study. Investigating the effect of parameters including pH, electrolysis time, current density, and 2,4-DNP concentration on the performance of the 3D/SEC-Fe-SBA-15 process in 2,4-DNP degradation was considered, and optimization of these parameters was done using the Taguchi design technique. Field emission scanning electron microscopy (FESEM), X-ray diffraction analysis (XRD), energy-dispersive X-ray spectroscopy mapping (EDX-mapping), transmission electron microscopy (TEM), and Fourier Transform Infrared Spectroscopy (FTIR)) were the analyses techniques used to support the successful synthesis of Fe-SBA-15 and G/β-PbO₂ anode. The optimum values obtained for pH, electrolysis time, current density, and 2,4-DNP concentration were 5.0, 60.0 min, 5.0 mA/cm², and 50.0 mg/L, respectively. The experimental removal efficiencies of 2,4-DNP, COD, and TOC using 3D/SEC-Fe-SBA-15 process, under the mentioned conditions, were obtained to be 96.3%, 88.28%, and 83.82%, respectively. In addition, the AOS value was developed from ?0.29 to + 0.88; this indicates the high mineralization of 2,4-DNP and improvement of the solution biodegradability. Detecting the intermediates produced during the degradation process was done by LC-MS analysis, and pathways for its degradation was proposed. Results were indicative of the high potential of the 3D/SEC-Fe-SBA-15 process for treating wastewater containing phenolic compounds, e.g., 2,4-DNP, and can provide acceptable efficiency.     

Investigations on 2,3'-Biquinolyls. 15. Regioselectivity of the Addition of Nitromethane Anion to 1'-Alkyl-3'-(2-quinolyl)quinolinium Halides

1'-R-3'-(2-Quinolyl)quinolinium halides react with nitromethane forming products of addition at the position 4', the 1'-R-4'-nitromethyl-1',4'-dihydro-2,3'-biquinolyls. A method has been developed for the synthesis of 1'-phenacyl-1',4'-dihydro-2,3'-biquinolyls based on the alkylation of 1',4'-dihydro-2,3'-biquinolyl with halogen derivatives in DMF.     

An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug–drug and drug–herb interaction by LC‐ESI/MS/MS

The aim of the present study was to evaluate the contribution of metabolites to drug–drug interaction and drug–herb interaction using the inhibition of CYP2D6 and CYP3A4 by metoprolol (MET) and its metabolites. The peak concentrations of unbound plasma concentration of MET, α‐hydroxy metoprolol (HM), O‐desmethyl metoprolol (ODM) and N‐desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively. The metabolites identified, HM and ODM, had a ratio of metabolic area under the concentration–time curve (AUC) to parent AUC of ≥0.25 when either total or unbound concentration of metabolite was considered. In vitro CYP2D6 and CYP3A4 inhibition by MET, HM and ODM study revealed that MET, HM and ODM were not inhibitors of CYP3A4‐catalyzed midazolam metabolism and CYP2D6‐catalyzed dextromethorphan metabolism. However, DIM only met the criteria of >10% of the total drug related material and <25% of the parent using unbound concentrations. If CYP inhibition testing is solely based on metabolite exposure, DIM metabolite would probably not be considered. However, the present study has demonstrated that DIM contributes significantly to in vitro drug–drug interaction. Copyright © 2016 John Wiley & Sons, Ltd.